TriangleNCT03894618 · STUDY IN CONTEXT
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Number of participants with treatment emergent adverse events
Number of participants with dose limiting toxicities (DLTs)
Based on review of all data, including safety, tolerability, PK, antitumor activity, and PD effects
Objective response rate per immune response evaluation criteria in solid tumors (iRECIST) for solid tumors
Number of participants with positive anti-drug antibody (ADA) titer, of those who were ADA negative at baseline
The Cmax is the maximum observed serum concentration of SL-279252 following single and multiple doses
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- trial label
- SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 6
- harms Count
- 15
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0000
- source section id
- NCT03894618-om-0000
- source outcome index
- 0
- endpoint
- Safety Profile of SL-279252
- endpoint definition
- Number of participants with treatment emergent adverse events
- time origin
- From Day 1 to 90 days after Last Dose of SL-279252
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0001
- source section id
- NCT03894618-om-0001
- source outcome index
- 1
- endpoint
- Maximum Tolerated Dose (MTD) of SL-279252
- endpoint definition
- Number of participants with dose limiting toxicities (DLTs)
- time origin
- From Day 1 to Day 21 (Schedule 1) or Day 28 (Schedule 2)
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- DLT evaluable population
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0002
- source section id
- NCT03894618-om-0002
- source outcome index
- 2
- endpoint
- Recommended Phase 2 Dose for SL-279252
- endpoint definition
- Based on review of all data, including safety, tolerability, PK, antitumor activity, and PD effects
- time origin
- Approximately 32 months
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0003
- source section id
- NCT03894618-om-0003
- source outcome index
- 3
- endpoint
- Overall Response Rate of SL-279252
- endpoint definition
- Objective response rate per immune response evaluation criteria in solid tumors (iRECIST) for solid tumors
- time origin
- Approximately 32 months
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- All treated population with solid tumors
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0004
- source section id
- NCT03894618-om-0004
- source outcome index
- 4
- endpoint
- Immunogenicity to SL-279252
- endpoint definition
- Number of participants with positive anti-drug antibody (ADA) titer, of those who were ADA negative at baseline
- time origin
- Approximately 32 months
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- For arms 0.0001 and 0.001 mg/kg of IV SL-279252, there were no subjects who were ADA negative at baseline. For arms 12.0 and 24.0 mg/kg of IV SL-279252, ADA samples were not collected.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0005
- source section id
- NCT03894618-om-0005
- source outcome index
- 5
- endpoint
- Maximum Serum Concentration (Cmax) of SL-279252
- endpoint definition
- The Cmax is the maximum observed serum concentration of SL-279252 following single and multiple doses
- time origin
- Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (cycle = 28 days)
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- PK Population - number analyzed may be less than the number of participants in a given cohort if samples were not available for analysis.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0000
- arm key
- OG000
- arm label
- SL-279252 (0.0001 mg/kg S1)
- regimen
- 0.0001 mg/kg of IV SL-279252 (Schedule 1)
- analyzed count
- 1
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03894618-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0000
- arm key
- OG001
- arm label
- SL-279252 (0.001 mg/kg S1)
- regimen
- 0.001 mg/kg of IV SL-279252 (Schedule 1)
- analyzed count
- 1
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03894618-om-0000#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0000
- arm key
- OG002
- arm label
- SL-279252 (0.003 mg/kg S1)
- regimen
- 0.003 mg/kg of IV SL-279252 (Schedule 1)
- analyzed count
- 2
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03894618-om-0000#groups/OG002
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0000
- arm key
- OG003
- arm label
- SL-279252 (0.01 mg/kg S1)
- regimen
- 0.01 mg/kg of IV SL-279252 (Schedule 1)
- analyzed count
- 1
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03894618-om-0000#groups/OG003
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0000
- arm key
- OG004
- arm label
- SL-279252 (0.03 mg/kg S1)
- regimen
- 0.03 mg/kg of IV SL-279252 (Schedule 1)
- analyzed count
- 2
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03894618-om-0000#groups/OG004
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0000
- arm key
- OG005
- arm label
- SL-279252 (0.1 mg/kg S1)
- regimen
- 0.1 mg/kg of IV SL-279252 (Schedule 1)
- analyzed count
- 3
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03894618-om-0000#groups/OG005
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0000
- arm key
- OG006
- arm label
- SL-279252 (0.3 mg/kg S1)
- regimen
- 0.3 mg/kg of IV SL-279252 (Schedule 1)
- analyzed count
- 4
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03894618-om-0000#groups/OG006
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0000
- arm key
- OG007
- arm label
- SL-279252 (1.0 mg/kg S1)
- regimen
- 1.0 mg/kg of IV SL-279252 (Schedule 1)
- analyzed count
- 6
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03894618-om-0000#groups/OG007
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0000
- arm key
- OG008
- arm label
- SL-279252 (3.0 mg/kg S1)
- regimen
- 3.0 mg/kg of IV SL-279252 (Schedule 1)
- analyzed count
- 6
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03894618-om-0000#groups/OG008
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0000
- arm key
- OG009
- arm label
- SL-279252 (6.0 mg/kg S1)
- regimen
- 6.0 mg/kg of IV SL-279252 (Schedule 1)
- analyzed count
- 4
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03894618-om-0000#groups/OG009
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0000
- arm key
- OG010
- arm label
- SL-279252 (12.0 mg/kg S1)
- regimen
- 12.0 mg/kg of IV SL-279252 (Schedule 1)
- analyzed count
- 4
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03894618-om-0000#groups/OG010
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- outcome key
- om-0000
- arm key
- OG011
- arm label
- SL-279252 (24.0 mg/kg S1)
- regimen
- 24.0 mg/kg of IV SL-279252 (Schedule 1)
- analyzed count
- 2
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03894618-om-0000#groups/OG011
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- harm key
- EG000
- source section id
- NCT03894618-ae
- event group key
- EG000
- event group label
- SL-279252 (0.0001 mg/kg S1)
- serious affected
- 0
- serious at risk
- 1
- other affected
- 1
- other at risk
- 1
- frequency threshold
- 5
- collection period
- Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- harm key
- EG001
- source section id
- NCT03894618-ae
- event group key
- EG001
- event group label
- SL-279252 (0.001 mg/kg S1)
- serious affected
- 1
- serious at risk
- 1
- other affected
- 1
- other at risk
- 1
- frequency threshold
- 5
- collection period
- Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- harm key
- EG002
- source section id
- NCT03894618-ae
- event group key
- EG002
- event group label
- SL-279252 (0.003 mg/kg S1)
- serious affected
- 0
- serious at risk
- 2
- other affected
- 2
- other at risk
- 2
- frequency threshold
- 5
- collection period
- Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- harm key
- EG003
- source section id
- NCT03894618-ae
- event group key
- EG003
- event group label
- SL-279252 (0.01 mg/kg S1)
- serious affected
- 0
- serious at risk
- 1
- other affected
- 1
- other at risk
- 1
- frequency threshold
- 5
- collection period
- Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- harm key
- EG004
- source section id
- NCT03894618-ae
- event group key
- EG004
- event group label
- SL-279252 (0.03 mg/kg S1)
- serious affected
- 0
- serious at risk
- 2
- other affected
- 2
- other at risk
- 2
- frequency threshold
- 5
- collection period
- Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- harm key
- EG005
- source section id
- NCT03894618-ae
- event group key
- EG005
- event group label
- SL-279252 (0.1 mg/kg S1)
- serious affected
- 1
- serious at risk
- 3
- other affected
- 3
- other at risk
- 3
- frequency threshold
- 5
- collection period
- Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- harm key
- EG006
- source section id
- NCT03894618-ae
- event group key
- EG006
- event group label
- SL-279252 (0.3 mg/kg S1)
- serious affected
- 1
- serious at risk
- 4
- other affected
- 4
- other at risk
- 4
- frequency threshold
- 5
- collection period
- Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- harm key
- EG007
- source section id
- NCT03894618-ae
- event group key
- EG007
- event group label
- SL-279252 (1.0 mg/kg S1)
- serious affected
- 3
- serious at risk
- 6
- other affected
- 4
- other at risk
- 6
- frequency threshold
- 5
- collection period
- Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- harm key
- EG008
- source section id
- NCT03894618-ae
- event group key
- EG008
- event group label
- SL-279252 (3.0 mg/kg S1)
- serious affected
- 1
- serious at risk
- 6
- other affected
- 6
- other at risk
- 6
- frequency threshold
- 5
- collection period
- Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- harm key
- EG009
- source section id
- NCT03894618-ae
- event group key
- EG009
- event group label
- SL-279252 (6.0 mg/kg S1)
- serious affected
- 1
- serious at risk
- 4
- other affected
- 3
- other at risk
- 4
- frequency threshold
- 5
- collection period
- Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- harm key
- EG010
- source section id
- NCT03894618-ae
- event group key
- EG010
- event group label
- SL-279252 (12.0 mg/kg S1)
- serious affected
- 0
- serious at risk
- 4
- other affected
- 4
- other at risk
- 4
- frequency threshold
- 5
- collection period
- Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-anal-cancer
- nct id
- NCT03894618
- harm key
- EG011
- source section id
- NCT03894618-ae
- event group key
- EG011
- event group label
- SL-279252 (24.0 mg/kg S1)
- serious affected
- 1
- serious at risk
- 2
- other affected
- 2
- other at risk
- 2
- frequency threshold
- 5
- collection period
- Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice